Navigation Links
SUPERA VERITAS® Receives Regulatory Approval in Australia
Date:4/28/2011

WEBSTER, Texas, April 28, 2011 /PRNewswire/ -- IDEV Technologies, Inc. (IDEV) today announced the firm has received approval from the Therapeutic Goods Administration (TGA), Australia's regulatory agency for medical drugs and devices, for the SUPERA VERITAS® stent system for use in biliary and peripheral procedures.

"We are pleased to receive the TGA approval, and look forward to launching SUPERA VERITAS in the Australian market later this year," said Christopher Owens, President and CEO of IDEV.  "Australia represents a leading market in the Asia-Pacific region, and we have established a wholly owned subsidiary, IDEV Medical Technologies PTY LTD, in Sydney to support the product registration and introduction of this unique next generation technology.  This is the first in a series of steps to extend our global footprint as well as our growth strategy in the Asia-Pacific region."

Australia represents an established growing peripheral vascular stent market, with an experienced base of endovascular physicians.

The SUPERA stent has been recognized as a different class of stent, based on proprietary technology and mechanical properties that result in unmatched radial strength and flexibility.  It provides a new treatment option for patients with biliary strictures or peripheral arterial disease (PAD).

About IDEV Technologies, IncorporatedIDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in interventional radiology, vascular surgery and cardiology.  IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.  For more information please visit www.idevmd.com.

The SUPERA stent is currently indicated in the U.S. for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe, Canada and Australia for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).Contact:

Donna LucchesiVice President Global MarketingIDEV Technologies, Incorporated(281) 525-2000
'/>"/>

SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. IDEV Announces Full Canadian Regulatory Approval for SUPERA VERITAS®
2. One-Year European Registry Data Released for Popliteal Stenting With SUPERA®
3. Long-Term European Data Released for SUPERA® Stent from IDEV Technologies
4. IDEV Technologies Announces FDA 510(k) Clearance for SUPERA VERITAS™
5. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
6. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
7. MAQUET Cardiovascular Receives 510(k) Clearance to Market the CARDIOHELP System in U.S.
8. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
9. STAAR Surgicals nanoFLEX™ Collamer® IOL Receives CE Mark Approval
10. NeoStems Suzhou Erye Pharmaceutical Receives Two Awards at the Chempharm Brand Summit 2011
11. Sound Surgical Technologies PowerX™ Lipo System Receives Clearance from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... KEY FINDINGS North America ... market in 2016 and is expected to continue in ... a large number of surgical procedures that are taking ... in the patient temperature management market.) Patient warming and ... of blood during surgeries, lowering the risks of neurological ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
(Date:12/8/2016)... , 8 de dezembro de 2016  A Mederi Therapeutics Inc . ... um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and broadcast during ... at Wuhan Union Hospital ...
Breaking Medicine Technology:
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, cancer ... announced the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s ... possible. With this in mind, SIGVARIS has created a new line of anti-embolism ... bed rest and provide the benefits of graduated compression when transitioning from recovery ...
Breaking Medicine News(10 mins):